Ten years' experience with benzbromarone in the management of gout and hyperuricaemia.

The results over 10 years in 200 patients (103 with gout and 97 with hyperuricaemia) treated with benzbromarone 75 - 120 mg/d are reported. The average stable decrease in the serum uric acid level was 54%. The severity and incidence of articular manifestations in the patients with gout were reduced by 75% before the end of the 1st year of treatment; relapses were very uncommon in the following years.

[Comparative study of uric acid concentration in serum and saliva of healthy or hyperuricemic subjects].

In normal or hyperuricemic subjects, the average values of serum and salivary uric acid concentration are very similar in each group of subjects. After absorption of a uricosuric drug, benzbromarone, a study of the variations of uric acid concentrations in the serum and saliva shows that they are parallel, which shows the stricts dependence salivary excretion on plasma concentration.